Immunostimulatory activity of palindromic immune modulatory oligonucleotides (imo) containing different lengths of palindromic segments

Abstract

The invention provides a palindromic immune modulatory nucleic acid. The invention also provides methods for generating, enhancing and modifying the immune response caused by palindromic immune modulatory compounds used for immunotherapy applications

1 . (canceled) 
     
     
         2 . A method for therapeutically treating a vertebrate having cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, skin disorders, allergy, asthma or a disease caused by a pathogen, such method comprising administering to the patient a palindromic immune modulatory oligonucleotide having a structure selected from 5′-TCG 1 TCG 1 TTCTC-Y-G 1 CTTG 1 CAAG 1 CT-5′, 5′-TCG 1 TCG 1 TTCTC-Y-GAG 1 CTTG 1 CAAG 1 CTCT-5′, 5′-TCG 1 TCG 1 TTCTC-Y-GAGAG 1 CTTG 1 CAAG 1 CTCTCT-5′, 5′-TCG 1 TCG 1 TTCTC-Y-GCCGCGCGGC-5′, 5′-TCG 1 TCG 1 TTAGA-Y-TG 1 CTG 1 CT-5′, or 5′-TCG 1 TCG 1 TTC-Y-G 1 CTTG 1 CAAG 1 CT-5′; wherein X is a glycerol linker, Y is C3-linker and G 1  is 7-deazaguanosine. 
     
     
         3 . The method according to  claim 2 , wherein the route of administration is selected from parenteral, oral, sublingual, transdermal, topical, mucosal, inhalation, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, gene gun, dermal patch, eye drop and mouthwash. 
     
     
         4 - 6 . (canceled) 
     
     
         7 . A method for preventing cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, skin disorders, allergy, asthma or a disease caused by a pathogen in a vertebrate, such method comprising administering to the vertebrate a palindromic immune modulatory oligonucleotide having a structure selected from 5′-TCG 1 TCG 1 TTCTC-Y-G 1 CTTG 1 CAAG 1 CT-5′, 5′-TCG 1 TCG 1 TTCTC-Y-GAG 1 CTTG 1 CAAG 1 CTCT-5′, 5′-TCG 1 TCG 1 TTCTC-Y-GAGAG 1 CTTG 1 CAAG 1 CTCTCT-5′, 5′-TCG 1 TCG 1 TTCTC-Y-GCCGCGCGGC-5′, 5′-TCG 1 TCG 1 TTAGA-Y-TG 1 CTG 1 CT-5′, or 5′-TCG 1 TCG 1 TTC-Y-G 1 CTTG 1 CAAG 1 CT-5′; wherein X is a glycerol linker, Y is C3-linker and G 1  is 7-deazaguanosine. 
     
     
         8 . The method according to  claim 7 , wherein the route of administration is selected from parenteral, oral, sublingual, transdermal, topical, mucosal, inhalation, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, gene gun, dermal patch, eye drop and mouthwash. 
     
     
         9 - 10 . (canceled) 
     
     
         11 . The method according to  claim 2 , further comprising administering an antibody, antisense oligonucleotide, protein, antigen, allergen, chemotherapeutic agent or adjuvant. 
     
     
         12 . (canceled) 
     
     
         13 . The method according to  claim 7 , further comprising administering an antibody, antisense oligonucleotide, protein, antigen, allergen, chemotherapeutic agent or adjuvant.